ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2011
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Clinicopathologic relevance of EpCAM and CD44 in pancreatic cancer: insights from a meta-analysis.Stem cell research & therapy · 2025Pooled it
- Article
- Derivation of pancreatic acinar cell carcinoma cell line HS-1 as a patient-derived tumor organoid.Cancer science · 2023Article
- Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC Cells.Cancers · 2023Article
- Pancreatic Organoids for Regenerative Medicine and Cancer Research.Frontiers in cell and developmental biology · 2022Review
- Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence.Cancers · 2021Article
- Genetic and molecular biology of bladder cancer among Iranian patients.Molecular genetics & genomic medicine · 2020Review
- Review
- Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.BMC cancer · 2019Article
- Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting.Journal of experimental & clinical cancer research : CR · 2018Review
- Shattering the castle walls: Anti-stromal therapy for pancreatic cancer.World journal of gastrointestinal oncology · 2018Review
- Pediatric sarcomas.Oncology letters · 2018Article
- Pancreatic β Cell Regeneration as a Possible Therapy for Diabetes.Cell metabolism · 2018Review
- Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma.International journal of clinical and experimental pathology · 2018Article
- Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.Disease markers · 2017Article
- Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.Cancer science · 2016Review
- Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers.Cancer biology & therapy · 2015Article
- Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.BMC cancer · 2014Article
- Article
- Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.Gastroenterology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-initiating cells of pancreatic ductal adenocarcinoma (PDAC) have been isolated based on expression of either CD133 or CD44. The authors aimed to visualize pancreatic cells simultaneously expressing both these cell surface markers by employing the same antibodies commonly used in cell-sorting studies. Normal and diseased pancreatic tissue, including 51 PDAC cases, were analyzed. CD44 and CD133 expression was determined by immunohistochemical double staining on formalin-fixed material and subcellular protein distribution evaluated by immunofluorescence/confocal microscopy. In the normal pancreas, CD44 and CD133 were coexpressed in the centroacinar regions but in non-overlapping subcellular compartments. As expected, CD44 was found mainly basolaterally, whereas CD133 was present on the apical/endoluminal membrane. This was also the case in chronically inflamed/atrophic pancreatic tissue and in PDAC. In some malignant ducts, CD44 was found at the apical cell membrane adjacent to but never overlapping with CD133 expression. CD44 level was significantly associated with the patient's lymph node status. In conclusion, a CD44+/CD133+ cell population does exist in the normal and neoplastic pancreas. The preferentially centroacinar localization of the doubly positive cells in the normal parenchyma suggests that this population could be of particular interest in attempts to identify tumor-initiating cells in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.